INT126895

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.96
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 3.59
Pain Relevance 0.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (SP1) nucleus (SP1) intracellular (SP1)
DNA binding (SP1) transcription factor binding (SP1) cytoplasm (SP1)
Anatomy Link Frequency
colon 2
SP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
COX2 4 99.24 Very High Very High Very High
COX-2 inhibitor 12 98.58 Very High Very High Very High
cINOD 42 92.80 High High
Analgesic 4 5.00 Very Low Very Low Very Low
Migraine 2 5.00 Very Low Very Low Very Low
rheumatoid arthritis 2 5.00 Very Low Very Low Very Low
Osteoarthritis 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colon Cancer 20 99.62 Very High Very High Very High
Apoptosis 72 98.44 Very High Very High Very High
Cancer 26 98.44 Very High Very High Very High
Pancreatic Cancer 8 97.32 Very High Very High Very High
INFLAMMATION 6 92.08 High High
Death 12 89.40 High High
Mouth Cancer 6 50.00 Quite Low
Immunotherapy Of Cancer 2 47.44 Quite Low
Metastasis 4 5.00 Very Low Very Low Very Low
Headache 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recently, Safe’s group reported that specificity protein 1 (Sp1) is degraded by tolfenamic acid to inhibit several cancer cell lines including pancreatic cancer [4, 18].
Protein_catabolism (degraded) of specificity protein 1 associated with cancer and pancreatic cancer
1) Confidence 0.96 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2901767 Disease Relevance 1.34 Pain Relevance 0
Recently, Safe’s group reported that specificity protein 1 (Sp1) is degraded by tolfenamic acid to inhibit several cancer cell lines including pancreatic cancer [4, 18].
Protein_catabolism (degraded) of Sp1 associated with cancer and pancreatic cancer
2) Confidence 0.47 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2901767 Disease Relevance 1.33 Pain Relevance 0
These results suggest that the antiangiogenic activity of COX-2 inhibitors in colon cancer cells is linked to activation of proteasome-dependent degradation of Sp1 and Sp4 proteins.
Protein_catabolism (degradation) of Sp1 in colon associated with colon cancer and cox-2 inhibitor
3) Confidence 0.18 Published 2005 Journal Mol. Pharmacol. Section Abstract Doc Link 15883203 Disease Relevance 0.45 Pain Relevance 0.13
Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins.
Protein_catabolism (degradation) of Sp1 in colon associated with colon cancer and cox2
4) Confidence 0.18 Published 2005 Journal Mol. Pharmacol. Section Title Doc Link 15883203 Disease Relevance 0.49 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox